Publikationen in Zusammenarbeit mit Forschern von Clínica Universitaria de Navarra (20)

2012

  1. Conjunctival vaccination against Brucella ovis in mice with mannosylated nanoparticles

    Journal of Controlled Release, Vol. 162, Núm. 3, pp. 553-560

2009

  1. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne

    Journal of Immunological Methods, Vol. 348, Núm. 1-2, pp. 1-8

2008

  1. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 70, Núm. 3, pp. 711-717

2007

  1. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles

    Vaccine, Vol. 25, Núm. 48, pp. 8123-8132

  2. Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections

    Expert Opinion on Drug Delivery, Vol. 4, Núm. 6, pp. 677-688

  3. Gantrez® AN nanoparticles as an adjuvant for oral immunotherapy with allergens

    Vaccine, Vol. 25, Núm. 29, pp. 5263-5271

  4. Intradermal immunization with ovalbumin-loaded poly-ε-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice

    Clinical and Experimental Allergy, Vol. 37, Núm. 2, pp. 287-295

2006

  1. Bioadhesive mannosylated nanoparticles for oral drug delivery

    Journal of Nanoscience and Nanotechnology

  2. Chemical and biological factors in the control of Brucella and brucellosis

    Current Drug Delivery, Vol. 3, Núm. 4, pp. 359-365

  3. Development of a novel vaccine delivery system based on gantrez nanoparticles

    Journal of Nanoscience and Nanotechnology

2005

  1. Bioadhesive properties of pegylated nanoparticles

    Expert Opinion on Drug Delivery, Vol. 2, Núm. 2, pp. 205-218

  2. Salmonella-like bioadhesive nanoparticles

    Journal of Controlled Release, Vol. 106, Núm. 1-2, pp. 1-13

2003

  1. Polymeric carriers for amphotericin B: In vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice

    Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 3, pp. 419-427

2001

  1. Promotion of platelet aggregation by sera from brucellosis patients with antiphosphatidylcholine antibodies

    Journal of Medical Microbiology, Vol. 50, Núm. 11, pp. 965-968

1998

  1. Anti-phosphatidylcholine antibodies in patients with brucellosis

    Journal of Medical Microbiology, Vol. 47, Núm. 1, pp. 49-54

1997

  1. Protective effect of liposomal gentamicin against systemic acute murine brucellosis

    Chemotherapy, Vol. 43, Núm. 3, pp. 204-210

1996

  1. Effect of composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortus

    Antimicrobial Agents and Chemotherapy, Vol. 40, Núm. 1, pp. 146-151

1995

  1. Antibiotic treatment induces an increase of the specific antibody levels in Brucella melitensis infected mice

    FEMS Immunology and Medical Microbiology, Vol. 12, Núm. 2, pp. 91-95

  2. Comparative activity of azithromycin and doxycycline against brucella spp. infection in mice

    Journal of Antimicrobial Chemotherapy, Vol. 36, Núm. 4, pp. 647-656

1993

  1. Brucella group 3 outer membrane proteins contain a heat-modifiable protein

    FEMS Microbiology Letters, Vol. 112, Núm. 2, pp. 141-145